Phoenix Biotech Acquisition Corp. (PBAX) to Combine with CERo Therapeutics in $112M Deal
Phoenix Biotech (NASDAQ:PBAX) has entered into a definitive agreement to combine with pre-cliinical drug developer CERo at an enterprise value of $112 million. San Francisco-based CERo is developing a line of potential cancer treatments and expects to file its first investigational new drug (IND) application in 2024. The combined company is expected to trade onRead More
To access this post, you must purchase 1 - User: Monthly Plan.